Chemistry:Cebaracetam

From HandWiki

Cebaracetam (INN; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.[1][2][3]

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam).[4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety.[4] The mechanism of action of cebaracetam is undefined or unknown.[1]

The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995.[1] It reached phase 2 clinical trials prior to its discontinuation.[1]

References

  1. 1.0 1.1 1.2 1.3 "Cebaracetam". 23 May 1995. https://adisinsight.springer.com/drugs/800001741. 
  2. "Stem Book 2018". 2018. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/stembook-2018.pdf. 
  3. "Fast systematic approach for the determination of drugs in biological fluids by fully automated high-performance liquid chromatography with on-line solid-phase extraction and automated cartridge exchange. Application to cebaracetam in human urine". Journal of Chromatography 577 (2): 335–340. June 1992. doi:10.1016/0378-4347(92)80255-o. PMID 1400764. 
  4. 4.0 4.1 "Cebaracetam". https://pubchem.ncbi.nlm.nih.gov/compound/65919.